We developed OxoScan-MS, a mass spectrometric acquisition technology for high-throughput quantification of glycopeptides. When applied to plasma of patients with COVID-19, OxoScan-MS revealed differential glycosylation in disease-relevant proteins. This approach offers potential for large-scale applications, moving beyond traditional protein abundance measurements to explore glycosylated protein biomarkers.
This is a preview of subscription content, log in via an institution to check access.
References
Anderson, N. L. & Anderson, N. G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1, 845–867 (2002). A review article that discusses the human plasma proteome.
Aebersold, R. & Mann, M. Mass-spectrometric exploration of proteome structure and function. Nature 537, 347–355 (2016). A review article that discusses how mass spectrometry can be used to study structure and function of proteins.
Bagdonaite, I. et al. Glycoproteomics. Nat. Rev. Methods Primers 2, 48 (2022). A review article that discusses methods to study the glycoproteome.
Messner, C. B. et al. Ultra-fast proteomics with Scanning SWATH. Nat. Biotechnol. 39, 846–854 (2021). This paper reports the Scanning SWATH technology used for the OxoScan Method.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: White, M. E. H. et al. Oxonium ion scanning mass spectrometry for large-scale plasma glycoproteomics. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-023-01067-5 (2023).
Rights and permissions
About this article
Cite this article
A high-throughput workflow for comprehensive glycopeptide mapping. Nat. Biomed. Eng 8, 212–213 (2024). https://doi.org/10.1038/s41551-023-01068-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41551-023-01068-4
- Springer Nature Limited